Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Sancai Granule is a Traditional Chinese Medicine (TCM) formulation developed by the Hubei Hospital of Traditional Chinese Medicine. It is primarily investigated for its potential to improve lung and kidney function in patients during the recovery period of COVID-19 (novel coronavirus pneumonia). The formulation is likely based on the classical Sancai Tang (Sancai Decoction), which traditionally incorporates ingredients such as *Panax ginseng* (Ren Shen), *Rehmannia glutinosa* (Di Huang), and *Asparagus cochinchinensis* (Tian Men Dong) to tonify Qi and Yin. In the context of post-viral recovery, Sancai Granule is used to address the TCM pattern of lung and kidney deficiency, aiming to alleviate respiratory symptoms and fatigue.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Sancai Granule (Hubei Provincial Traditional Chinese Medical Hospital).